You have 9 free searches left this month | for more free features.

cpx-351

Showing 1 - 25 of 30

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Myeloid Tumor Trial in Memphis (CPX-351, MHA)

Recruiting
  • Myeloid Neoplasm
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 20, 2023

Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Tampa (CPX-351)

Active, not recruiting
  • Lymphoid Leukemia
  • +3 more
  • CPX-351
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022

Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes Trial in La Jolla,

Recruiting
  • Acute Myelogenous Leukemia (AML) Due to Therapy
  • Acute Myeloid Leukemia With Myelodysplasia-Related Changes
  • Orange, California
  • +2 more
Nov 30, 2022

Acute Myeloid Leukemia Trial in United States (CPX-351, Venetoclax, Midostaurin)

Active, not recruiting
  • Acute Myeloid Leukemia
  • CPX-351
  • +3 more
  • Duarte, California
  • +9 more
Jan 3, 2023

Acute Myeloid Leukemia Trial in United States (CPX-351, Venetoclax)

Completed
  • Acute Myeloid Leukemia
  • Duarte, California
  • +7 more
Nov 7, 2022

Acute Myeloid Leukemia (AML) in Remission Trial in Washington (CPX-351)

Recruiting
  • Acute Myeloid Leukemia (AML) in Remission
  • CPX-351
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
May 3, 2022

Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)

Terminated
  • Leukemia, Myeloid, Acute
  • Denver, Colorado
  • +4 more
May 10, 2022

MDS Trial in Tampa, Saint Louis, Seattle (CPX-351, Research skin biopsy, Research blood draw)

Active, not recruiting
  • Myelodysplastic Syndromes
  • CPX-351
  • +3 more
  • Tampa, Florida
  • +2 more
Apr 1, 2022

Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, MDS Trial in Cleveland (CPX-351)

Recruiting
  • Refractory Acute Myeloid Leukemia
  • +2 more
  • CPX-351
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Mar 15, 2022

MDS Trial in New Haven (CPX-351)

Withdrawn
  • MDS
  • CPX-351
  • New Haven, Connecticut
    Yale University; Smilow Cancer Center
Jan 6, 2022

Acute Myeloid Leukemia Trial in Miami (CPX-351, Midostaurin, Busulfan)

Recruiting
  • Acute Myeloid Leukemia
  • CPX-351
  • +5 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health of South Florida
Jul 27, 2022

Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Neoplasm
  • (no location specified)
Apr 24, 2023

Leukemia, Myeloid, Acute Trial in New York (CPX-351)

Active, not recruiting
  • Leukemia, Myeloid, Acute
  • CPX-351
  • New York, New York
    Weill Cornell Medical College
Dec 10, 2021

MDS, Leukemia, Myeloid, Acute, Leukemia, Relapsed Adult Acute Myeloid Trial in New York (CPX-351, Fludarabine, Melphalan)

Active, not recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • CPX-351
  • +4 more
  • New York, New York
    Weill Cornell Medical College
Jan 26, 2022

Acute Myeloid Leukemia Trial in New York (CPX-351, Gemtuzumab Ozogamicin)

Recruiting
  • Acute Myeloid Leukemia
  • CPX-351
  • Gemtuzumab Ozogamicin
  • New York, New York
    Weill Cornell Medical College
Dec 21, 2021

Myelodysplastic Syndrome (MDS) Trial in Cleveland (CPX-351)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • CPX-351
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
Apr 21, 2021

Leukemia, Myeloid, Acute Trial (Cytarabine, Venetoclax, CPX-351)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • (no location specified)
Nov 25, 2022

Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in Canada, United States (CPX-351)

Completed
  • Hematologic Malignancy
  • +4 more
  • CPX-351
  • Washington, District of Columbia
  • +12 more
Jul 20, 2021

Acute Myeloid Leukemia, Myeloproliferative Syndrome Trial in France (CPX-351)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myeloproliferative Syndrome
  • CPX-351
  • Amiens, France
  • +33 more
Feb 7, 2022

Newly Diagnosed Secondary or High Risk AML Trial in Spain (CPX-351)

Active, not recruiting
  • Newly Diagnosed Secondary or High Risk AML
  • CPX-351
  • Badalona, Spain
  • +11 more
Jul 9, 2021

MDS, AML Trial in Austria, Germany (CPX-351, Daunorubicin, Cytarabine)

Recruiting
  • MDS
  • AML
  • CPX-351
  • +3 more
  • Linz, Austria
  • +26 more
Sep 9, 2022

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lymphoma Trial in Cincinnati (CPX-351)

Completed
  • Acute Myeloid Leukemia
  • +7 more
  • CPX-351
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Nov 6, 2020

High Risk Acute Myeloid Leukemia Trial in Canada, United States (CPX-351, 7+3 (cytarabine and daunorubicin))

Completed
  • High Risk Acute Myeloid Leukemia
  • CPX-351
  • 7+3 (cytarabine and daunorubicin)
  • Birmingham, Alabama
  • +42 more
Jul 28, 2020

A Post-Marketing Observational Study of VYXEOS™

Completed
  • Acute Myeloid Leukemia With Myelodysplasia-Related Changes
  • Therapy-Related Acute Myeloid Leukemia
  • CPX-351
  • Indianapolis, Indiana
  • +6 more
Aug 4, 2020

Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) Trial in United States

Withdrawn
  • Acute Myeloid Leukemia (AML)
  • +2 more
  • CPX-351
  • Los Angeles, California
  • +4 more
Mar 12, 2018